European pharma chiefs warn of competitive decline without urgent policy reforms

Nine chief executives from Europe's largest pharmaceutical companies have issued a stark warning to their governments: the continent is falling behind in the global race to develop new drugs, and without urgent policy changes, that gap will only widen.

The executives, representing some of the industry's most established names, point to a familiar culprit: the machinery of European regulation moves too slowly. Drug trials take longer to approve here than in the United States or China. The bureaucratic path from laboratory discovery to patient access stretches across months and years in ways that competitors have learned to compress. Meanwhile, government funding for pharmaceutical research and development lags behind what American and Chinese firms can access. The result, these leaders argue, is a slow erosion of Europe's position as a center of pharmaceutical innovation—a sector that has historically been one of the continent's strengths.

The nine pharma chairs framed their appeal not as a complaint but as an urgent call for survival. They told European policymakers plainly that the continent does not currently value what the pharmaceutical industry does. That message carries weight because these are not marginal players. They lead companies that employ tens of thousands across Europe, that conduct research in European laboratories, that have built supply chains and manufacturing capacity on European soil. Their investment decisions—where to locate new research facilities, where to funnel development budgets, where to place clinical trials—shape the economic landscape of the continent.

What makes this moment distinct is the specificity of the threat. The executives are not merely warning of abstract competitive decline. They are signaling that future investment may flow elsewhere. If Europe continues to move slowly on regulatory approval, if government support for innovation remains inadequate, then the next generation of drug development may happen in Boston or Shanghai instead of Basel or Cambridge. The jobs, the intellectual capital, the tax revenue, the prestige of being a hub for cutting-edge medicine—all of it could migrate.

The regulatory question sits at the heart of their complaint. The European Medicines Agency, which oversees drug approvals across the bloc, operates under a framework designed for thoroughness and caution. That caution has value; it protects patients from unsafe or ineffective treatments. But it also means that a drug approved in the United States can take substantially longer to reach European patients. In a competitive landscape where speed matters—where being first to market with a breakthrough treatment carries enormous commercial advantage—that delay translates into lost opportunity. American and Chinese regulators have moved to streamline their processes, creating faster pathways for promising drugs. Europe has not kept pace.

The funding gap compounds the problem. Government investment in pharmaceutical research varies widely across European countries, but the overall picture shows Europe spending less per capita on drug development than the United States. Private companies fill some of that gap, but they make investment decisions based on return prospects. If Europe's regulatory environment makes it harder to recoup research costs quickly, companies will invest their capital where conditions are more favorable.

The nine executives are not asking for deregulation or for corners to be cut on safety. They are asking for modernization—for regulatory processes that can move faster without sacrificing rigor, for government policies that make Europe an attractive place to conduct pharmaceutical research, for a recognition that innovation in this sector matters to Europe's economic future and global standing. Their warning carries an implicit timeline: act now, or watch the industry gradually reorient itself toward other continents. The choice, they are saying, belongs to European policymakers.